SCHEMBL20207692

SCHEMBL20207692

CCCOc1cc([C@H](C)NS(=O)(=O)CCCCCNCC(=O)OCC)ccc1F

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DUT P33316 17/20 0.57
LTA4H P09960 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20338498 0.90 DUT (0.49) DUT
SCHEMBL20338497 0.90 DUT (0.49) DUT
SCHEMBL21325248 0.90 DUT (0.55) DUT
SCHEMBL18374471 0.89 DUT (0.55) DUTLTA4H
SCHEMBL20373244 0.89 DUT (0.54) DUTLTA4H
SCHEMBL20374120 0.88 DUT (0.58) DUT
SCHEMBL20351499 0.88 DUT (0.58) DUT
SCHEMBL20351491 0.87 DUT (0.57) DUT
SCHEMBL20201967 0.87 CALM1 (0.43) DUTLTA4H
SCHEMBL22751582 0.83 DUT (0.55) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230126280-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2023-04-27 US disclosed
US-20220402879-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-12-22 US disclosed
US-11518746-B2 Nitrogen ring linked deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-12-06 US disclosed
US-11247984-B2 Uracil containing compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-02-15 US disclosed
US-11174271-B2 6-membered uracil isosteres CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-16 US disclosed
US-11014924-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-05-25 US disclosed
US-20210061767-A1 NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-03-04 US disclosed
US-10858344-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-12-08 US disclosed
US-10829457-B2 Nitrogen ring linked deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-11-10 US disclosed
US-10570098-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-25 US disclosed
US-10562860-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-18 US disclosed
US-20200039966-A1 URACIL CONTAINING COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-06 US disclosed
US-20190330210-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
US-20190276410-A1 NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-12 US disclosed
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-05 US disclosed
US-20180194736-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-12 US disclosed
US-20180186737-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-05 US disclosed
WO-2018098207-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194736-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885
US-11174271-B2 6-membered uracil isosteres UNG, DUT, DPYD DUT 2/4885LTA4H 2676/4885
US-20210061767-A1 NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, DPYD, TYMP DUT 1/4885LTA4H 2722/4885
US-20220402879-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885
US-20190330210-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885
US-10858344-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885
US-10829457-B2 Nitrogen ring linked deoxyuridine triphosphatase inhibitors DUT, DPYD, TYMP DUT 1/4885LTA4H 2722/4885
US-11014924-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885
US-10570098-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885
US-20200039966-A1 URACIL CONTAINING COMPOUNDS UNG, DPYD, DUT DUT 3/4885LTA4H 2692/4885
US-11518746-B2 Nitrogen ring linked deoxyuridine triphosphatase inhibitors DUT, DPYD, TYMP DUT 1/4885LTA4H 2722/4885
US-11247984-B2 Uracil containing compounds UNG, DPYD, DUT DUT 3/4885LTA4H 2692/4885
US-10562860-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885
US-20180186737-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885
US-20190276410-A1 NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, DPYD, TYMP DUT 1/4885LTA4H 2722/4885
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES UNG, DUT, DPYD DUT 2/4885LTA4H 2676/4885
US-20230126280-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885LTA4H 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.